Desensitization With Imlifidase for HLA-Incompatible Deceased Donor Kidney Transplantation: A Delphi International Expert Consensus
- PMID: 39867871
- PMCID: PMC11758882
- DOI: 10.3389/ti.2024.13886
Desensitization With Imlifidase for HLA-Incompatible Deceased Donor Kidney Transplantation: A Delphi International Expert Consensus
Abstract
Highly sensitized (HS) patients in need of kidney transplantation (KTx) typically spend a longer time waiting for compatible kidneys, are unlikely to receive an organ offer, and are at increased risk of antibody-mediated rejection (AMR). Desensitization using imlifidase, which is more rapid and removes total body immunoglobulin G (IgG) to a greater extent than other methods, enables transplantation to occur between HLA-incompatible (HLAi) donor-recipient pairs and allows patients to have greater access to KTx. However, when the project was launched there was limited data and clinical experience with desensitization in general and with imlifidase specifically. Hence, this Delphi methodology was used to reach a consensus from a multi-disciplinary team (MDT) of experts from 15 countries on the management of HS patients undergoing imlifidase HLAi from a deceased donor (DD) KTx. This Delphi consensus provides clinical practice guidance on the use of imlifidase in the end-to-end management of HS patients undergoing an HLAi DD KTx and supports centers in the development of guidelines for the utilization and integration of imlifidase into clinical practice.
Keywords: HLA incompatible; HLAi; desensitization; imlifidase; kidney transplantation.
Copyright © 2025 Furian, Heemann, Bengtsson, Bestard, Binet, Böhmig, Boletis, Briggs, Claas, Couzi, Cozzi, Crespo, De Vries, Diekmann, Durlik, Glotz, Helantera, Jackson, Jordan, Kuypers, Lefaucheur, Legendre, Lorant, Maggiore, Mamode, Marinaki, Massart, Müller, Oberbauer, Renders, Roelen, Taupin, Viklický, Vittoraki, de Weerd and Naesens.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Belgian Consensus Guidelines Within Eurotransplant on Imlifidase-enabled Deceased Donor Kidney Transplantation in Highly Sensitized Patients.Transplantation. 2025 Aug 1;109(8):1274-1283. doi: 10.1097/TP.0000000000005388. Epub 2025 May 5. Transplantation. 2025. PMID: 40320582
-
Spanish guidelines for kidney transplantation in highly sensitized patients with donor-specific anti-HLA antibodies.Transplant Rev (Orlando). 2025 Jul;39(3):100919. doi: 10.1016/j.trre.2025.100919. Epub 2025 Apr 3. Transplant Rev (Orlando). 2025. PMID: 40209457 Review.
-
Kidney transplant outcomes in HLA desensitized patients with pretransplant CDC and/or FCM positive crossmatches.Front Immunol. 2025 Jun 23;16:1612462. doi: 10.3389/fimmu.2025.1612462. eCollection 2025. Front Immunol. 2025. PMID: 40625754 Free PMC article.
-
Normothermic and hypothermic machine perfusion preservation versus static cold storage for deceased donor kidney transplantation.Cochrane Database Syst Rev. 2024 Jul 9;7(7):CD011671. doi: 10.1002/14651858.CD011671.pub3. Cochrane Database Syst Rev. 2024. PMID: 38979743 Free PMC article.
-
The experiences of adults who are on dialysis and waiting for a renal transplant from a deceased donor: a systematic review.JBI Database System Rev Implement Rep. 2015 Mar 12;13(2):169-211. doi: 10.11124/jbisrir-2015-1973. JBI Database System Rev Implement Rep. 2015. PMID: 26447040
Cited by
-
Belimumab to Aid Pre-Transplant Immunological Risk-Stratification by Uncovering Broader HLA-Specific Memory B-Cell Profiles.HLA. 2025 Jun;105(6):e70285. doi: 10.1111/tan.70285. HLA. 2025. PMID: 40522199 Free PMC article.
References
-
- Schinstock CA, Smith BH, Montgomery RA, Jordan SC, Bentall AJ, Mai M, et al. Managing Highly Sensitized Renal Transplant Candidates in the Era of Kidney Paired Donation and the New Kidney Allocation System: Is There Still a Role for Desensitization? Clin Transpl (2019) 33(12):e13751. 10.1111/CTR.13751 - DOI - PubMed
-
- Schinstock CA, Mannon RB, Budde K, Chong AS, Haas M, Knechtle S, et al. Recommended Treatment for Antibody-Mediated Rejection after Kidney Transplantation: The 2019 Expert Consensus from the Transplantation Society Working Group. Transplantation (2020) 104(5):911–22. 10.1097/TP.0000000000003095 - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials